ADAMTS13 and COVID-19: In the 11 cases reported in the literature, ADAMTS-13 activity levels were < 10%, and 8 cases (72%) had elevated ADAMTS-13 inhibitors or antibody levels.[1] In COVID-19 patients, ADAMTS-13 activity levels are typically reduced, creating a pro-thrombotic environment.